Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma

Neoplasia (United States)

Volumn 18, Issue 2, 2016, Pages 121-132

  Tiffen, Jessamy ^a   Wilson, Stephen ^b   Gallagher, Stuart J ^a   Hersey, Peter ^a   Filipp, Fabian V ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GSK 126; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; EZH2 PROTEIN, HUMAN; GSK126; INDOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ARTICLE; CANCER INHIBITION; CANCER PATIENT; CANCER PROGNOSIS; CELL CYCLE; CELL DIFFERENTIATION; COHORT ANALYSIS; CONTROLLED STUDY; CUTANEOUS MELANOMA; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GENE AMPLIFICATION; GENE REPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; MELANOMA CELL; MELANOMA CELL LINE; METASTASIS INHIBITION; MICROARRAY ANALYSIS; PRIORITY JOURNAL; RNA SEQUENCE; SOMATIC COPY NUMBER AMPLIFICATION; SOMATIC MUTATION; ANTAGONISTS AND INHIBITORS; COPY NUMBER VARIATION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; MELANOMA; MUTATION; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

DNA COPY NUMBER VARIATIONS; DNA METHYLATION; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNITY, INNATE; INDOLES; MELANOMA; MICROARRAY ANALYSIS; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRIDONES;

EID: 84963949085     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2016.01.003     Document Type: Article

References (32)

1. Mills AA Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins. Nat Rev Cancer 2010, 10:669-682.
2. Baylin SB, Jones PA A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 2011, 11:726-734.
3. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden JM, et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006, 439:871-874.
4. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, Waghorn K, Zoi K, Ross FM, Reiter A, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 2010, 42:722-726.
5. Ntziachristos P, Tsirigos A, Van Vlierberghe P, Nedjic J, Trimarchi T, Flaherty MS, Ferres-Marco D, da Ros V, Tang Z, Siegle J, et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med 2012, 18:298-301.
6. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, Paul JE, Boyle M, Woolcock BW, Kuchenbauer F, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010, 42:181-185.
7. De Carvalho DD, Binato R, Pereira WO, Leroy JM, Colassanti MD, Proto-Siqueira R, Bueno-Da-Silva AE, Zago MA, Zanichelli MA, Abdelhay E, et al. BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients. Oncogene 2011, 30:223-233.
8. Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Richon VM, Copeland RA Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A 2010, 107:20980-20985.
9. McCabe MT, Graves AP, Ganji G, Diaz E, Halsey WS, Jiang Y, Smitheman KN, Ott HM, Pappalardi MB, Allen KE, et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci U S A 2012, 109:2989-2994.
10. Guan J, Gupta R, Filipp FV Cancer systems biology of TCGA SKCM: Efficient detection of genomic drivers in melanoma. Sci Rep 2015, 5:7857-7866.
11. Zingg D, Debbache J, Schaefer SM, Tuncer E, Frommel SC, Cheng P, Arenas-Ramirez N, Haeusel J, Zhang Y, Bonalli M, et al. The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. Nat Commun 2015, 6:6051-6067.
12. Barsotti AM, Ryskin M, Zhong W, Zhang WG, Giannakou A, Loreth C, Diesl V, Follettie M, Golas J, Lee M, et al. Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth. Oncotarget 2015, 6:2928-2938.
13. Tiffen J, Gallagher SJ, Hersey P EZH2: an emerging role in melanoma biology and strategies for targeted therapy. Pigment Cell Melanoma Res 2015, 28(1):21-30.
14. Tiffen JC, Gunatilake D, Gallagher SJ, Gowrishankar K, Heinemann A, Cullinane C, Dutton-Regester K, Pupo GM, Strbenac D, Yang JY, et al. Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes. Oncotarget 2015, 6(29):27023-27036.
15. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, et al. A landscape of driver mutations in melanoma. Cell 2012, 150:251-263.
16. Antonysamy S, Condon B, Druzina Z, Bonanno JB, Gheyi T, Zhang F, MacEwan I, Zhang A, Ashok S, Rodgers L, et al. Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by X-ray crystallographic analysis of the EZH2-SET domain. PLoS One 2013, 8(12):e84147.
17. Sahasrabuddhe AA, Chen X, Chung F, Velusamy T, Lim MS, Elenitoba-Johnson KS Oncogenic Y641 mutations in EZH2 prevent Jak2/beta-TrCP-mediated degradation. Oncogene 2015, 34:445-454.
18. Hobert O, Jallal B, Ullrich A Interaction of Vav with ENX-1, a putative transcriptional regulator of homeobox gene expression. Mol Cell Biol 1996, 16:3066-3073.
19. Fan T, Jiang S, Chung N, Alikhan A, Ni C, Lee CC, Hornyak TJ EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. Mol Cancer Res 2011, 9:418-429.
20. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A, Diaz E, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012, 492:108-112.
21. Hou P, Liu D, Dong J, Xing M The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells. Cell Cycle 2012, 11:286-295.
22. Rodriguez-Paredes M, Esteller M Cancer epigenetics reaches mainstream oncology. Nat Med 2011, 17:330-339.
23. Hoon DS, Spugnardi M, Kuo C, Huang SK, Morton DL, Taback B Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 2004, 23:4014-4022.
24. Liu S, Ren S, Howell P, Fodstad O, Riker AI Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. Pigment Cell Melanoma Res 2008, 21:545-558.
25. Conway K, Edmiston SN, Khondker ZS, Groben PA, Zhou X, Chu H, Kuan PF, Hao H, Carson C, Berwick M, et al. DNA-methylation profiling distinguishes malignant melanomas from benign nevi. Pigment Cell Melanoma Res 2011, 24:352-360.
26. Eferl R, Wagner EF AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003, 3:859-868.
27. Ezhkova E, Pasolli HA, Parker JS, Stokes N, Su IH, Hannon G, Tarakhovsky A, Fuchs E Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. Cell 2009, 136:1122-1135.
28. Lee ST, Li Z, Wu Z, Aau M, Guan P, Karuturi RK, Liou YC, Yu Q Context-specific regulation of NF-kappaB target gene expression by EZH2 in breast cancers. Mol Cell 2011, 43:798-810.
29. Spranger S, Bao R, Gajewski TF Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 2015, 523(7559):231-235.
30. Abou El Hassan M, Huang K, Eswara MB, Zhao M, Song L, Yu T, Liu Y, Liu JC, McCurdy S, Ma A, et al. Cancer Cells Hijack PRC2 to Modify Multiple Cytokine Pathways. PLoS One 2015, 10:e0126466.
31. Holling TM, Bergevoet MW, Wilson L, Van Eggermond MC, Schooten E, Steenbergen RD, Snijders PJ, Jager MJ, Van den Elsen PJ A role for EZH2 in silencing of IFN-gamma inducible MHC2TA transcription in uveal melanoma. J Immunol 2007, 179:5317-5325.
32. Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, Ly A, Lie WR, Hildebrand WH, Mardis ER, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 2015, 348:803-808.